Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Aadvark, which will list on the Nasdaq under the ticker “AARD” Feb. 13, will have the opportunity to bring in roughly $14.1 ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been its lead cancer-fighting therapy, chop 50% of its workforce and look at ...